Literature DB >> 17604880

Immune response to two different dosing schedules of the anthrax vaccine precipitated (AVP) vaccine.

Matthew J Hepburn1, E Hugh Dyson, Andrew J H Simpson, Karen E Brenneman, Nicola Bailey, Lucy Wilkinson, Rebecca Hornby, Alfred J Mateczun, Matthew G Bell, Leslie W J Baillie.   

Abstract

A pilot study compared the immune response of regular (0, 3, 6, 32 weeks) and extended (0, 10, 13, 32 weeks) schedules of the UK anthrax vaccine (anthrax vaccine precipitated, AVP). Concentrations of antibodies to protective antigen (PA) were higher (p<0.05) among recipients of the extended (n=7) versus regular schedule (n=6) at week 32, and 2 weeks after the second and third vaccinations. Toxin neutralisation assay levels and anti-lethal factor antibodies followed patterns similar to anti-PA antibodies. Extending the interval between the first two AVP vaccinations may produce a stronger immune response, but persistence of this effect needs further study.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17604880     DOI： 10.1016/j.vaccine.2007.05.018

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  12 in total

1.  Anthrax vaccination induced anti-lethal factor IgG: fine specificity and neutralizing capacity.

Authors:  Sherry R Crowe; Lori Garman; Renata J M Engler; A Darise Farris; Jimmy D Ballard; John B Harley; Judith A James
Journal:  Vaccine       Date:  2011-03-21       Impact factor: 3.641

2.  Lethal factor antibodies contribute to lethal toxin neutralization in recipients of anthrax vaccine precipitated.

Authors:  Eric K Dumas; Lori Garman; Hannah Cuthbertson; Sue Charlton; Bassam Hallis; Renata J M Engler; Shyamal Choudhari; William D Picking; Judith A James; A Darise Farris
Journal:  Vaccine       Date:  2017-05-11       Impact factor: 3.641

3.  Anthrax Vaccine Precipitated Induces Edema Toxin-Neutralizing, Edema Factor-Specific Antibodies in Human Recipients.

Authors:  Eric K Dumas; Timothy Gross; Jason Larabee; Lance Pate; Hannah Cuthbertson; Sue Charlton; Bassam Hallis; Renata J M Engler; Limone C Collins; Christina E Spooner; Hua Chen; Jimmy Ballard; Judith A James; A Darise Farris
Journal:  Clin Vaccine Immunol       Date:  2017-11-06

4.  The early humoral immune response to Bacillus anthracis toxins in patients infected with cutaneous anthrax.

Authors:  Karen E Brenneman; Mehmet Doganay; Arya Akmal; Stanley Goldman; Darrell R Galloway; Alfred J Mateczun; Alan S Cross; Leslie W Baillie
Journal:  FEMS Immunol Med Microbiol       Date:  2011-04-15

5.  An anthrax subunit vaccine candidate based on protective regions of Bacillus anthracis protective antigen and lethal factor.

Authors:  Les W Baillie; Theresa B Huwar; Stephen Moore; Gabriela Mellado-Sanchez; Liliana Rodriguez; Brendan N Neeson; Helen C Flick-Smith; Dominic C Jenner; Helen S Atkins; Rebecca J Ingram; Danny M Altmann; James P Nataro; Marcela F Pasetti
Journal:  Vaccine       Date:  2010-08-04       Impact factor: 3.641

6.  Characterization of the native form of anthrax lethal factor for use in the toxin neutralization assay.

Authors:  Hang Lu; Jason Catania; Katalin Baranji; Jie Feng; Mili Gu; Janet Lathey; Diane Sweeny; Hannah Sanford; Kavita Sapru; Terry Patamawenu; June-Home Chen; Alan Ng; Zenbework Fesseha; Stefanie Kluepfel-Stahl; Jacob Minang; David Alleva
Journal:  Clin Vaccine Immunol       Date:  2013-05-01

7.  A Phase 1 study of the blood-stage malaria vaccine candidate AMA1-C1/Alhydrogel with CPG 7909, using two different formulations and dosing intervals.

Authors:  Ruth D Ellis; Gregory E D Mullen; Mark Pierce; Laura B Martin; Kazutoyo Miura; Michael P Fay; Carole A Long; Donna Shaffer; Allan Saul; Louis H Miller; Anna P Durbin
Journal:  Vaccine       Date:  2009-05-15       Impact factor: 3.641

8.  Evaluation of immune response to recombinant Bacillus anthracis LFD1-PA4 chimeric protein.

Authors:  H Mirhaj; H Honari; E Zamani
Journal:  Iran J Vet Res       Date:  2019       Impact factor: 1.376

Review 9.  Anthrax prophylaxis: recent advances and future directions.

Authors:  E Diane Williamson; Edward Hugh Dyson
Journal:  Front Microbiol       Date:  2015-09-24       Impact factor: 5.640

10.  A Comparison of the Adaptive Immune Response between Recovered Anthrax Patients and Individuals Receiving Three Different Anthrax Vaccines.

Authors:  Thomas R Laws; Tinatin Kuchuloria; Nazibriola Chitadze; Stephen F Little; Wendy M Webster; Amanda K Debes; Salome Saginadze; Nikoloz Tsertsvadze; Mariam Chubinidze; Robert G Rivard; Shota Tsanava; Edward H Dyson; Andrew J H Simpson; Matthew J Hepburn; Nino Trapaidze
Journal:  PLoS One       Date:  2016-03-23       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.